GlassScriptPhysician profile
Trudy E Day
NPI 1265590814
$9,584.95
in general payments reported to CMS, 2019-2025
32 companies · $2,146 in 2025
The $2,146 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,552 · 2022: $1,974 · 2023: $1,846 · 2024: $2,066 · 2025: $2,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,947 · Travel and Lodging: $661 · Consulting Fee: $300 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,947.23 |
| Travel and Lodging | $660.87 |
| Consulting Fee | $300.00 |
| Education | $151.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,848.67 | 2021-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,403.72 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $919.35 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $641.98 | 2021-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $641.39 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $630.45 | 2021-2025 | |
| Mylan Specialty L.P. | $576.02 | 2021-2024 | Yupelri |
| Genzyme Corporation | $354.47 | 2021-2025 | |
| Harmony Biosciences LLC | $335.71 | 2021-2023 | Wakix |
| Insmed, INC. | $317.92 | 2021-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $311.04 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $257.19 | 2021-2024 | Tezspire, Tavneos |
| Actelion Pharmaceuticals US, INC. | $250.87 | 2021-2024 | Opsumit, Uptravi |
| Verona Pharma, INC. | $186.16 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $165.81 | 2024-2025 | Lumryz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $127.77 | 2021-2025 | Glassia, Entyvio |
| Axsome Therapeutics, INC. | $95.28 | 2023-2024 | Sunosi |
| Electromed, INC. | $80.12 | 2021-2025 | Smartvest |
| Viatris Specialty LLC | $64.94 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $55.72 | 2021 | |
| Lilly USA, LLC | $51.36 | 2025 | Zepbound |
| Philips North America LLC | $44.42 | 2021 | |
| Eisai INC. | $32.09 | 2021 | |
| Resmed Corp | $30.62 | 2021-2024 | |
| United Therapeutics Corporation | $28.76 | 2023 | Tyvaso |
| Alexion Pharmaceuticals, INC. | $25.78 | 2021 | |
| Pulmonx Corporation | $22.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $19.78 | 2021 | |
| Pfizer INC. | $19.42 | 2024 | |
| Zoll Respicardia, INC. | $18.01 | 2023 | Remede System |
| Vifor Pharma, INC. | $14.90 | 2024 | Zemaira |
| La Jolla Pharmaceutical Company | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trudy Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.